Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study.
Carson Ka-Lok LoCalvin Ka-Fung LoAdam S KomorowskiVictor LeungNancy MaticSusan McKennaSantiago Perez-PatrigeonPrameet M ShethChristopher F LoweZain ChaglaAnthony D BaiPublished in: BMC research notes (2024)
No differences were demonstrated in hospitalization, ICU admission, or mortality rates within 30 days between sotrovimab-treated patients with BA.1 versus BA.2 infection. More real-world data may be helpful to properly assess sotrovimab's effectiveness against infections due to specific emerging COVID-19 variants.
Keyphrases
- randomized controlled trial
- systematic review
- coronavirus disease
- sars cov
- intensive care unit
- emergency department
- cardiovascular events
- study protocol
- electronic health record
- gene expression
- copy number
- cardiovascular disease
- cross sectional
- type diabetes
- mechanical ventilation
- dna methylation
- double blind
- artificial intelligence
- respiratory syndrome coronavirus
- newly diagnosed
- genome wide